# Ribosomes in Mitochondria: Structure, Function, and Biogenesis

## Introduction to Mitochondrial Ribosomes

Mitochondria are semi-autonomous organelles that retain a vestigial genome and the machinery required to express it. Central to this expression is the mitochondrial ribosome, or mitoribosome, a ribonucleoprotein complex that catalyzes [protein synthesis](/blog/guides/protein-synthesis-a-step-by-step-guide-to-transcription-and-translation) within the mitochondrial matrix. First identified in the 1960s through electron microscopy and sucrose gradient sedimentation of isolated mitochondria, mitoribosomes were initially assumed to closely resemble their bacterial counterparts. Subsequent biochemical and structural work revealed that they are highly specialized machines, diverged substantially from both prokaryotic and eukaryotic cytoplasmic ribosomes.

The essential role of mitoribosomes is to translate the handful of messenger RNAs (mRNAs) encoded by the [mitochondrial genome](/blog/guides/mitochondrial-genome). In humans, this genome is a circular, double-stranded DNA molecule of 16,569 base pairs that encodes 13 polypeptides, 22 transfer RNAs (tRNAs), and 2 ribosomal RNAs (rRNAs). The 13 polypeptides are all hydrophobic core subunits of the oxidative phosphorylation (OXPHOS) system—the pathway that generates most cellular ATP. Without functional mitoribosomes, these subunits cannot be produced, OXPHOS collapses, and the cell is deprived of its primary energy source. This explains why mutations in mitoribosome components cause severe, often fatal, human diseases.

Understanding mitoribosomes requires a comparative framework. The cytoplasmic ribosomes that translate nuclear mRNAs are 80S particles in eukaryotes (40S small subunit + 60S large subunit), while bacterial ribosomes are 70S (30S + 50S). Mitoribosomes occupy a middle ground in size but are unique in composition. In mammals, they sediment at 55S, with a 28S small subunit and a 39S large subunit. This unusual sedimentation coefficient reflects not a smaller particle overall, but a dramatic shift in the RNA-to-protein ratio, a theme explored throughout this article.

## Types of Ribosomes in Mitochondria

Mitoribosomes are not uniform across eukaryotes. Their size, composition, and even the genetic system they translate vary considerably between lineages. This diversity is a product of independent evolutionary trajectories following the endosymbiotic origin of mitochondria, with different eukaryotic groups losing or retaining different components of the ancestral bacterial translation machinery.

### Mammalian Mitoribosomes

Mammalian mitoribosomes are the best-characterized. They sediment at 55S and are composed of a 28S small subunit (SSU) and a 39S large subunit (LSU). The SSU contains a 12S rRNA (approximately 950 nucleotides in humans) and 30 mitochondrial ribosomal proteins (MRPs). The LSU contains a 16S rRNA (approximately 1,550 nucleotides) and 52 MRPs. The total molecular mass is roughly 2.7 MDa.

The most striking feature of mammalian mitoribosomes is their protein-to-RNA ratio. Whereas bacterial ribosomes are about 65% RNA by mass, mammalian mitoribosomes are only about 30% RNA. This means the rRNA has been drastically reduced and replaced by additional proteins. Many of these proteins are not homologous to bacterial ribosomal proteins; they are eukaryotic additions that stabilize the structure and compensate for the shortened rRNA. The sedimentation coefficient of 55S, lower than the bacterial 70S, is a direct consequence of this reduced RNA content, which decreases the particle's buoyant density and hydrodynamic behavior.

### Plant and Fungal Mitoribosomes

Plant mitoribosomes are larger and more complex. In Arabidopsis thaliana, the mitoribosome sediments at approximately 78S and contains rRNA molecules that are expanded relative to bacteria, not reduced. The SSU rRNA is around 2,000 nucleotides, and the LSU rRNA around 3,500 nucleotides, with numerous additional proteins—over 80 in the LSU alone. Plant mitoribosomes also retain more bacterial features, including a 5S rRNA, which is absent in mammalian mitoribosomes. This suggests that the plant lineage has expanded its mitochondrial translation machinery independently, acquiring new proteins and RNA elements.

Fungal mitoribosomes, particularly those of Saccharomyces cerevisiae, are intermediate. They sediment at about 74S and contain rRNA molecules of intermediate length (15S and 21S). Yeast mitoribosomes have fewer proteins than mammalian ones but still show a reduced RNA content relative to bacteria. They also differ functionally: yeast mitochondria translate only 7–8 proteins, compared to 13 in mammals, reflecting the smaller yeast [mitochondrial genome](/blog/guides/mitochondrial-genome).

These differences matter practically. Drugs that inhibit bacterial ribosomes, such as chloramphenicol, also inhibit mitoribosomes across species, but the sensitivity varies. Yeast mitoribosomes are highly sensitive to chloramphenicol, while mammalian mitoribosomes are moderately sensitive. This has implications for antibiotic therapy, discussed later.

## Structure of Mitochondrial Ribosomes

The high-resolution structures of mammalian mitoribosomes, solved by cryo-electron microscopy (cryo-EM) in the 2010s, revealed their architecture in atomic detail. The overall shape is similar to that of bacterial ribosomes—a small subunit that binds mRNA and tRNA, and a large subunit that catalyzes peptide bond formation—but the surface features and internal organization are markedly different.

### Small Subunit (28S)

The 28S subunit in mammals is responsible for decoding: it binds the mRNA and ensures that each codon is matched with the correct aminoacyl-tRNA. Its core is the 12S rRNA, which folds into a structure that is a minimized version of the bacterial 16S rRNA. Many of the peripheral helices present in bacteria are absent, and the remaining helices are stabilized by additional proteins.

The 30 proteins of the 28S subunit include 14 that are homologous to bacterial SSU proteins (e.g., uS2, uS3, uS5, uS7) and 16 that are mitochondrial-specific (e.g., mS29, mS31, mS33). The mitochondrial-specific proteins often occupy the surface of the subunit, forming extended domains that protrude into the matrix. One notable feature is the mRNA entrance channel, which is lined by mitochondrial-specific proteins that may help recruit mitochondrial mRNAs, which lack the Shine-Dalgarno sequences used by bacteria.

The decoding center, where codon-anticodon recognition occurs, is conserved. The key nucleotides of the 12S rRNA that monitor base pairing are identical to those in bacteria. This conservation explains why aminoglycoside antibiotics, which bind to the decoding center, can also target mitoribosomes, a point elaborated in the clinical section.

### Large Subunit (39S)

The 39S subunit catalyzes peptide bond formation at the peptidyl transferase center (PTC), located in the 16S rRNA. The PTC is the most conserved part of the entire ribosome, and in mitoribosomes it retains the same RNA-based catalytic mechanism as in bacteria. The 16S rRNA, however, is substantially shorter than the bacterial 23S rRNA, and many of its peripheral domains are replaced by proteins.

The 52 proteins of the 39S subunit include 24 that are homologous to bacterial LSU proteins (e.g., uL2, uL3, uL4, uL16) and 28 that are mitochondrial-specific (e.g., mL38, mL40, mL48). A striking feature of the mammalian 39S subunit is the presence of a large, extended polypeptide exit tunnel. This tunnel is lined with mitochondrial-specific proteins and is significantly wider than the bacterial tunnel. This adaptation accommodates the highly hydrophobic proteins synthesized by mitoribosomes, which must be inserted into the inner mitochondrial membrane co-translationally.

Another unique feature is the presence of a tRNA-binding site for the mitochondrial tRNA (tRNA^Met) that is structurally distinct from bacterial systems. The 39S subunit also contains a pentatricopeptide repeat (PPR) protein, mS39, which is involved in mRNA binding and coordination with the small subunit.

The following table summarizes the key structural parameters of bacterial, mammalian cytoplasmic, and mammalian mitochondrial ribosomes:

| Feature | Bacterial (E. coli) | Mammalian Cytoplasmic | Mammalian Mitochondrial |
|---------------------------|---------------------|-----------------------|-------------------------|
| Sedimentation coefficient | 70S | 80S | 55S |
| Small subunit | 30S | 40S | 28S |
| Large subunit | 50S | 60S | 39S |
| rRNA mass (SSU + LSU) | 16S + 23S (~4,500 nt) | 18S + 28S (~5,000 nt) | 12S + 16S (~2,500 nt) |
| Number of proteins | 54 | 80 | 82 |
| RNA percentage by mass | ~65% | ~50% | ~30% |
| mRNA source | Bacterial | Nuclear | Mitochondrial |

## Prokaryotic Origins and Evolutionary Significance

The endosymbiotic theory posits that mitochondria descend from an alpha-proteobacterium that was engulfed by an ancestral eukaryotic cell approximately 1.5–2 billion years ago. Over evolutionary time, most of the bacterial genome was transferred to the nucleus, but a small set of genes was retained in the organelle. The retention of these genes is not random; they encode proteins that are highly hydrophobic and difficult to import from the cytoplasm, or whose expression must be tightly regulated in response to the organelle's redox state.

Mitoribosomes are direct descendants of the bacterial ribosome. This is evident at multiple levels. The catalytic core of the mitoribosome—the peptidyl transferase center and the decoding center—is composed of rRNA sequences that are clearly homologous to bacterial rRNA. Many mitoribosomal proteins are orthologs of bacterial ribosomal proteins, and the overall mechanism of translation (initiation, elongation, termination, and recycling) is bacterial-like, using bacterial-type initiation factors (IF2, IF3) and elongation factors (EF-Tu, EF-G) that are encoded in the nucleus and imported into mitochondria.

The similarities have practical consequences. Antibiotics that target the bacterial ribosome often also inhibit the mitoribosome. Chloramphenicol, which binds to the bacterial 50S subunit and inhibits peptidyl transferase, also binds to the mitoribosomal LSU. Tetracyclines, which block tRNA binding to the bacterial A-site, similarly affect mitoribosomes. This cross-reactivity is the basis for the use of chloramphenicol as a tool to specifically inhibit mitochondrial translation in cultured cells, but it also underlies the mitochondrial toxicity of certain antibiotics in patients.

However, the evolutionary divergence is equally important. The massive protein accretion in mitoribosomes—the addition of dozens of mitochondrial-specific proteins—is a unique evolutionary event. These proteins are not derived from the bacterial ancestor; they are eukaryotic inventions that were added to the ribosome over time. Some of these proteins are derived from other bacterial proteins that were repurposed, while others are entirely novel. This process, termed "ribosomal protein expansion," has occurred in parallel in cytoplasmic ribosomes, but the mitoribosome represents the most extreme example.

The functional significance of this protein expansion is still being unraveled. Some mitochondrial-specific proteins are required for ribosome assembly, others for mRNA recruitment, and others for membrane tethering. The expansion likely allowed the mitoribosome to adapt to the unique challenges of translating highly hydrophobic proteins in a membrane-rich environment, while also integrating with the mitochondrial gene expression machinery that is distinct from the bacterial one.

## Function of Ribosomes in Mitochondria

The primary function of mitoribosomes is to translate the 13 mRNAs encoded by the mitochondrial genome. In humans, these mRNAs are unusual: they are almost entirely devoid of 5' and 3' untranslated regions, and some lack a complete stop codon, relying instead on a post-transcriptional polyadenylation that creates the stop. The mRNAs are also not capped, and they are translated using a streamlined initiation mechanism that does not require the cap-binding complex or scanning.

### Translation of Membrane Proteins

All 13 mitochondrial-encoded proteins are subunits of the OXPHOS complexes:

- **Complex I (NADH:ubiquinone oxidoreductase):** 7 subunits (ND1–ND6, ND4L)
- **Complex III (cytochrome bc1 complex):** 1 subunit (cytochrome b)
- **Complex IV (cytochrome c oxidase):** 3 subunits (COX1, COX2, COX3)
- **Complex V (ATP synthase):** 2 subunits (ATP6, ATP8)

These proteins are all highly hydrophobic, with multiple transmembrane domains. For example, ND1 has 8 transmembrane helices, and COX1 has 12. The mitoribosome must therefore synthesize these proteins and deliver them directly into the inner mitochondrial membrane, where they assemble with nuclear-encoded subunits to form the functional OXPHOS complexes.

The translation of these proteins is not uniform. The 13 mRNAs are translated at different rates, and the expression of each is regulated in response to cellular energy demand. For instance, the translation of COX1 mRNA is regulated by the availability of heme, while the translation of ATP6 mRNA is regulated by the membrane potential. This regulation is mediated by mRNA-specific translational activators, which are nuclear-encoded proteins that bind to the 5' untranslated regions of mitochondrial mRNAs and recruit the mitoribosome.

### Co-translational Insertion

The insertion of newly synthesized proteins into the inner mitochondrial membrane is coupled to translation. This process is mediated by the oxidase assembly factor OXA1L, a homolog of the bacterial YidC and the chloroplast Alb3. OXA1L is an inner membrane protein that binds to the mitoribosome's large subunit and receives the nascent polypeptide as it emerges from the exit tunnel. The polypeptide is then inserted into the membrane in a loop or helical hairpin conformation, with the transmembrane domains partitioning into the lipid bilayer.

This co-translational insertion is essential. If translation is uncoupled from insertion, the hydrophobic nascent chains aggregate in the matrix, and the OXPHOS complexes cannot assemble. The coupling is achieved through a physical interaction between the mitoribosome and OXA1L, which is mediated by the mitochondrial-specific proteins of the large subunit that line the exit tunnel. The structure of the mitoribosome–OXA1L supercomplex, solved by cryo-EM, shows that the ribosome is docked onto the membrane with the exit tunnel aligned with the OXA1L channel.

The translation cycle itself follows the bacterial paradigm. Initiation requires the binding of the small subunit to the mRNA, facilitated by initiation factors mtIF2 and mtIF3. The start codon is typically AUG, but AUA and AUU are also used in mitochondria, and the initiator tRNA is a specialized formylmethionyl-tRNA (tRNA^fMet). Elongation uses mitochondrial elongation factors mtEF-Tu (which delivers aminoacyl-tRNAs to the A-site) and mtEF-G (which catalyzes translocation). Termination occurs when a release factor, mtRF1 or mtRF1a, recognizes a stop codon (UAA or UAG) and promotes hydrolysis of the completed polypeptide.

## Biogenesis and Assembly of Mitoribosomes

Mitoribosome biogenesis is a complex process that requires the coordinated expression of genes from two genomes. The rRNAs (12S and 16S) are transcribed from the mitochondrial genome, while all 82 ribosomal proteins are encoded by nuclear genes, translated on cytoplasmic ribosomes, and imported into the mitochondrial matrix. This dual-origin synthesis requires a dedicated import machinery and a series of assembly factors that orchestrate the stepwise construction of the ribosome.

### Import of Proteins

Mitochondrial ribosomal proteins (MRPs) are synthesized as precursors in the cytoplasm. Most contain an N-terminal mitochondrial targeting sequence (MTS), a positively charged amphipathic helix of 20–40 amino acids. The MTS is recognized by the translocase of the outer membrane (TOM complex), which delivers the precursor to the translocase of the inner membrane (TIM23 complex). Translocation across the inner membrane is driven by the membrane potential (Δψ) and by the presequence translocase-associated motor (PAM), which uses the hydrolysis of ATP by mtHsp70 to pull the protein into the matrix. Once inside, the MTS is cleaved by the mitochondrial processing peptidase (MPP).

Some MRPs lack a cleavable MTS and instead use internal targeting signals. These proteins are imported through a different pathway, often involving the TIM22 complex, which inserts them into the inner membrane. This is particularly relevant for the mitochondrial-specific proteins that are associated with the membrane-facing surface of the mitoribosome.

The import of MRPs is not a trivial process. The proteins must fold into their mature conformations only after reaching the matrix, and they must avoid aggregation in the highly protein-dense mitochondrial environment. Chaperones such as mtHsp70 and mtHsp60 assist in this process, binding to the imported proteins and preventing premature folding or misfolding.

### Assembly Factors

The assembly of the 28S and 39S subunits is a stepwise process that occurs in the mitochondrial matrix, often in association with the inner membrane. This process requires a set of assembly factors that are not part of the mature ribosome but are essential for its construction. These factors include RNA helicases, GTPases, and RNA-modifying enzymes.

The assembly of the small subunit begins with the transcription of the 12S rRNA. The rRNA is modified at specific nucleotides—methylations and pseudouridylations—by enzymes such as TFB1M (which dimethylates two adenines near the 3' end) and RPUSD4 (which pseudouridylates a specific uridine). These modifications are required for the rRNA to fold correctly and for the subsequent binding of ribosomal proteins.

A key assembly factor is the GTPase mtGTPBP10, which binds to the 12S rRNA and promotes the recruitment of the first set of ribosomal proteins. Another factor, ERAL1, is an RNA-binding protein that stabilizes the 12S rRNA and prevents its degradation. The assembly proceeds through a series of intermediates, each characterized by a specific set of bound proteins and assembly factors. The final steps involve the removal of assembly factors and the incorporation of the last ribosomal proteins, including the mitochondrial-specific ones that form the surface of the subunit.

The assembly of the large subunit is even more complex, involving over 20 assembly factors. The 16S rRNA is transcribed and modified by enzymes such as MRM1 (which methylates a specific guanine) and MRM2 (which methylates a specific uridine). The GTPase mtGTPBP7 (also known as MTG1) plays a critical role in the early steps, while the RNA helicase DDX28 is required for the correct folding of the 16S rRNA. The assembly factors also include the protein MTERF4, which forms a complex with the RNA methyltransferase NSUN4 and directs the methylation of the 16S rRNA.

The final step of mitoribosome biogenesis is the joining of the 28S and 39S subunits to form the 55S monosome. This step is regulated by the GTPase mtGTPBP6, which promotes subunit joining, and by the anti-association factor mtIF3, which prevents premature joining. The mature mitoribosome then associates with the inner membrane, where it engages in translation.

## Methods to Study Mitochondrial Ribosomes

The study of mitoribosomes has been revolutionized by technological advances, particularly in structural biology and high-throughput sequencing. These methods have provided unprecedented insight into the structure, function, and dynamics of mitoribosomes.

### Cryo-EM

Cryo-electron microscopy (cryo-EM) is the method of choice for determining mitoribosome structures. Unlike [X-ray crystallography](/knowledge/molecular-biology/x-ray-crystallography), which requires large, well-ordered crystals, cryo-EM can visualize single particles in vitreous ice. This is essential for mitoribosomes, which are difficult to crystallize due to their conformational heterogeneity and their tendency to aggregate.

The first near-atomic structures of the mammalian mitoribosome were solved by cryo-EM in 2014–2015, at resolutions of 3–4 Å. These structures revealed the complete architecture of the 28S and 39S subunits, including the positions of all 82 proteins and the folding of the rRNA. Subsequent structures have captured the mitoribosome in different functional states—during initiation, elongation, and termination—and in complex with accessory factors such as OXA1L and translational activators.

Cryo-EM has also been used to study mitoribosome assembly intermediates. By isolating mitoribosomes from cells depleted of specific assembly factors, researchers have trapped and visualized the assembly process at different stages. These structures have revealed the order of protein binding and the conformational changes that occur as the subunits mature.

### [Ribosome Profiling](/knowledge/molecular-biology/ribosome-profiling)

[Ribosome profiling](/knowledge/molecular-biology/ribosome-profiling), also known as Ribo-seq, is a technique that provides a genome-wide snapshot of translation. The method involves treating cells with a translation inhibitor (such as cycloheximide for cytoplasmic ribosomes or chloramphenicol for mitoribosomes), digesting the unprotected mRNA with a nuclease, and then sequencing the ribosome-protected fragments. The resulting reads map to the mRNA and reveal the positions of ribosomes, allowing the determination of translation rates, codon usage, and the sites of translation initiation and termination.

For mitoribosomes, ribosome profiling has been adapted to specifically capture mitochondrial translation. This requires the use of chloramphenicol to stall mitoribosomes, followed by the isolation of mitochondria and the extraction of mitochondrial ribosome-protected fragments. This approach has revealed that mitochondrial mRNAs are translated at different rates, with some mRNAs (such as COX1) being translated much more efficiently than others. It has also identified the precise start codons used by each mitochondrial mRNA and has shown that some mRNAs are translated with a "leaderless" mechanism, where the ribosome binds directly to the start codon without scanning.

Ribosome profiling has also been used to study the effects of mitoribosome mutations on translation. By comparing the ribosome-protected fragments from wild-type and mutant cells, researchers can identify which mRNAs are affected and at what stage of translation the defect occurs. This has been instrumental in understanding the molecular basis of mitochondrial diseases.

### Sucrose Gradient Sedimentation

Sucrose gradient sedimentation is a classic biochemical method used to separate mitoribosomes from other cellular components and to analyze their subunit composition. Mitochondria are lysed in a buffer containing magnesium ions (typically 10 mM MgCl₂) to stabilize the ribosomes, and the lysate is layered on top of a 10–30% sucrose gradient. The gradient is then centrifuged at high speed (e.g., 100,000 × g for 16 hours) to separate particles by their sedimentation coefficient.

Fractions are collected from the bottom of the gradient, and the absorbance at 260 nm is measured to detect RNA-containing particles. The 55S monosome, 39S large subunit, and 28S small subunit appear as distinct peaks. This method is used to assess the integrity of mitoribosomes, to monitor the effects of mutations or drugs on subunit association, and to purify mitoribosomes for downstream analysis.

Sucrose gradients are also used to analyze mitoribosome assembly intermediates. By using gradients with different conditions (e.g., low magnesium to dissociate subunits), researchers can separate the various assembly stages and analyze their protein and RNA composition by mass spectrometry or Northern blotting.

## Clinical Relevance and Common Pitfalls

Mitoribosomes are essential for life, and defects in their function cause a class of severe human diseases known as mitochondrial disorders. These diseases are characterized by impaired OXPHOS, leading to energy deficiency in high-demand tissues such as the brain, heart, and skeletal muscle.

### Mitochondrial Diseases

Mutations in mitoribosome components cause a spectrum of clinical syndromes, including:

- **Leigh syndrome:** A progressive neurodegenerative disorder characterized by bilateral brain lesions, hypotonia, and respiratory failure. Mutations in the mitoribosomal proteins MRPS34, MRPS22, and MRPL44 have been identified in Leigh syndrome patients.
- **Combined OXPHOS deficiency:** A condition in which multiple OXPHOS complexes are deficient, leading to a wide range of symptoms including cardiomyopathy, hepatopathy, and lactic acidosis. Mutations in the assembly factor TFB1M, which is required for 12S rRNA methylation, cause this condition.
- **Perrault syndrome:** A disorder characterized by sensorineural hearing loss and ovarian dysfunction. Mutations in the mitoribosomal protein MRPL50 have been linked to this syndrome.
- **Deafness and aminoglycoside sensitivity:** A maternally inherited predisposition to hearing loss triggered by aminoglycoside antibiotics. The most common cause is a mutation in the 12S rRNA gene (m.1555A>G), which makes the mitoribosome more similar to the bacterial ribosome and increases its affinity for aminoglycosides, leading to toxicity.

The molecular mechanisms of these diseases are diverse. Some mutations impair the assembly of the mitoribosome, leading to reduced levels of the 55S monosome. Others affect the catalytic activity of the ribosome, reducing the rate of translation. Still others disrupt the interaction between the mitoribosome and the inner membrane, impairing co-translational insertion.

The diagnosis of mitoribosome disorders typically involves a combination of clinical evaluation, biochemical assays (e.g., measurement of OXPHOS complex activities), and genetic testing. The treatment is largely supportive, as there are no curative therapies. However, there is active research into pharmacological approaches, such as read-through agents that suppress stop codons, and gene therapy strategies that deliver functional copies of the affected genes.

### Common Misconceptions

Students frequently encounter several misconceptions about mitoribosomes. These are worth addressing directly:

1. **"Mitoribosomes are the same as bacterial ribosomes."** While mitoribosomes share a common ancestor with bacterial ribosomes, they have diverged significantly. The protein-to-RNA ratio, the sedimentation coefficient, and the presence of mitochondrial-specific proteins all distinguish them. The catalytic core is conserved, but the periphery is not.

2. **"Mitoribosomes are 70S."** In mammals, mitoribosomes are 55S. The 70S value applies to bacteria and to the mitoribosomes of some plants and fungi, but not to mammals. Always specify the organism when discussing mitoribosome size.

3. **"Mitochondria make all their own proteins."** Mitochondria make only 13 proteins in humans. The vast majority of mitochondrial proteins (approximately 1,500) are nuclear-encoded and imported from the cytoplasm. The mitoribosome is responsible for a small, but essential, subset.

4. **"Antibiotics that target bacteria do not affect mitochondria."** Many antibiotics that target the bacterial ribosome also inhibit the mitoribosome. This is the basis for the mitochondrial toxicity of aminoglycosides, chloramphenicol, and tetracyclines. The clinical relevance is particularly important in patients with pre-existing mitochondrial dysfunction.

5. **"Mitoribosomes translate all mitochondrial mRNAs equally."** Translation is highly regulated. Each of the 13 mRNAs has its own set of translational activators, and the rates of translation vary widely. This regulation is essential for the stoichiometric assembly of OXPHOS complexes.

## Frequently Asked Questions

### What type of ribosome is found in mitochondria?

Mitochondria contain mitoribosomes, which are distinct from both bacterial (70S) and cytoplasmic eukaryotic (80S) ribosomes. In mammals, mitoribosomes sediment at 55S and are composed of a 28S small subunit and a 39S large subunit. They are ribonucleoprotein complexes with a high protein-to-RNA ratio.

### Are there different types of ribosomes in mitochondria?

Yes, mitoribosomes vary across species. Mammalian mitoribosomes are 55S with reduced rRNA, while plant mitoribosomes are larger (approximately 78S) with expanded rRNA, and fungal mitoribosomes are intermediate (approximately 74S). The protein composition also differs significantly between lineages.

### What is the function of ribosomes in mitochondria?

Mitoribosomes translate the 13 mRNAs encoded by the mitochondrial genome. These mRNAs encode essential hydrophobic subunits of the oxidative phosphorylation complexes I, III, IV, and V. The mitoribosome synthesizes these proteins and inserts them co-translationally into the inner mitochondrial membrane.

### Why are mitochondrial ribosomes similar to bacterial ribosomes?

Mitoribosomes are descendants of the bacterial ribosome from the alpha-proteobacterium that gave rise to mitochondria through endosymbiosis. The catalytic core (peptidyl transferase center and decoding center) is conserved, as are many ribosomal proteins and translation factors. This similarity explains the sensitivity of mitoribosomes to certain antibiotics.

### How do mitochondrial ribosomes differ from cytoplasmic ribosomes?

Mitoribosomes differ in size (55S vs. 80S), rRNA content (reduced vs. expanded), protein composition (mitochondrial-specific proteins vs. eukaryotic-specific proteins), and mRNA source (mitochondrial vs. nuclear). Mitoribosomes also have a wider polypeptide exit tunnel to accommodate hydrophobic membrane proteins.

### Can antibiotics that target bacteria also affect mitochondrial ribosomes?

Yes. Antibiotics such as chloramphenicol, tetracyclines, and aminoglycosides bind to the bacterial ribosome and also inhibit the mitoribosome. This cross-reactivity can cause mitochondrial toxicity, particularly in patients with mitochondrial mutations that increase antibiotic binding affinity, such as the m.1555A>G mutation in the 12S rRNA gene.

### What happens if mitochondrial ribosomes are defective?

Defects in mitoribosomes impair the synthesis of the 13 OXPHOS subunits, leading to reduced ATP production and increased reactive oxygen species. This causes mitochondrial diseases such as Leigh syndrome, combined OXPHOS deficiency, and Perrault syndrome, with symptoms including neurodegeneration, cardiomyopathy, and hearing loss.

## Key Takeaways

- Mitoribosomes are specialized ribosomes that translate the 13 protein-coding mRNAs of the mitochondrial genome, all of which are hydrophobic subunits of the oxidative phosphorylation system.
- Mammalian mitoribosomes sediment at 55S (28S + 39S) and have a protein-to-RNA ratio of approximately 70:30, the inverse of bacterial ribosomes.
- Mitoribosomes evolved from bacterial ribosomes via endosymbiosis, retaining a conserved catalytic core but acquiring dozens of mitochondrial-specific proteins.
- The structure of the mitoribosome is adapted for co-translational insertion of membrane proteins, with a widened exit tunnel and a physical interaction with the OXA1L insertase.
- Mitoribosome biogenesis requires the import of all 82 ribosomal proteins from the cytoplasm and their assembly with mitochondrial-encoded rRNAs, orchestrated by numerous assembly factors.
- Ribosome profiling and cryo-EM have been instrumental in revealing the structure, assembly, and translational dynamics of mitoribosomes.
- Defects in mitoribosomes cause severe mitochondrial diseases, and certain antibiotics can inhibit mitoribosomes, leading to mitochondrial toxicity.

## Further Reading

- Nadler F, Lavdovskaia E, Richter-Dennerlein R. *Maintaining mitochondrial ribosome function: The role of ribosome rescue and recycling factors*. RNA biology. 2022. [PubMed 34923906](https://doi.org/10.1080/15476286.2021.2015561)
- Chrzanowska-Lightowlers ZM, Lightowlers RN. *Translation in Mitochondrial Ribosomes*. Methods in [molecular biology](/blog/careers/molecular-biology) (Clifton, N.J.). 2023. [PubMed 37166631](https://doi.org/10.1007/978-1-0716-3171-3_4)
- Dalla Rosa I et al. *MPV17L2 is required for ribosome assembly in mitochondria*. [Nucleic acids research](/blog/news/nucleic-acids-research). 2014. [PubMed 24948607](https://doi.org/10.1093/nar/gku513)
- Ott M et al. *Mba1, a membrane-associated ribosome receptor in mitochondria*. The EMBO journal. 2006. [PubMed 16601683](https://doi.org/10.1038/sj.emboj.7601070)
- Feaga HA et al. *Human Cells Require Non-stop Ribosome Rescue Activity in Mitochondria*. PLoS genetics. 2016. [PubMed 27029019](https://doi.org/10.1371/journal.pgen.1005964)
- Seely SM, Gagnon MG. *Mechanisms of ribosome recycling in bacteria and mitochondria: a structural perspective*. RNA biology. 2022. [PubMed 35485608](https://doi.org/10.1080/15476286.2022.2067712)

## Related Topics

- [Ribosome Profiling](/knowledge/molecular-biology/ribosome-profiling)
- [Ribosome Structure](/knowledge/molecular-biology/ribosome-structure)
- [Ribosome Definition](/knowledge/molecular-biology/ribosome-definition)
- [Ribosome Diagram](/knowledge/molecular-biology/ribosome-diagram)
- [Ribosome Picture](/knowledge/molecular-biology/ribosome-picture)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)